Quality_NN and_CC methods_NNS of_IN developing_VBG practice_NN guidelines_NNS Abstract_NP |_SYM Background_NN |_SYM It_PP is_VBZ not_RB known_VBN whether_IN there_EX are_VBP differences_NNS in_IN the_DT quality_NN and_CC recommendations_NNS between_IN evidence-based_JJ (_( EB_NP )_) and_CC consensus-based_JJ (_( CB_NP )_) guidelines_NNS ._SENT We_PP used_VBD breast_NN cancer_NN guidelines_NNS as_IN a_DT case_NN study_NN to_TO assess_VB for_IN these_DT differences_NNS ._SENT Methods_NNS |_SYM Five_JJ different_JJ instruments_NNS to_TO evaluate_VB the_DT quality_NN of_IN guidelines_NNS were_VBD identified_VBN by_IN a_DT literature_NN search_NN ._SENT We_PP also_RB searched_VBD MEDLINE_NP and_CC the_DT Internet_NN to_TO locate_VB 8_CD breast_NN cancer_NN guidelines_NNS ._SENT These_DT guidelines_NNS were_VBD classified_VBN in_IN three_CD categories_NNS :_: evidence_NN based_VBN ,_, consensus_NN based_VBN and_CC consensus_NN based_VBN with_IN no_DT explicit_JJ consideration_NN of_IN evidence_NN (_( CB-EB_NP )_) ._SENT Each_DT guideline_NN was_VBD evaluated_VBN by_IN three_CD of_IN the_DT authors_NNS using_VBG each_DT of_IN the_DT instruments_NNS ._SENT For_IN each_DT guideline_NN we_PP assessed_VBD the_DT agreement_NN among_IN 14_CD decision_NN points_NNS which_WDT were_VBD selected_VBN from_IN the_DT NCCN_NP (_( National_NP Cancer_NP Comprehensive_NP Network_NP )_) guidelines_NNS algorithm_NN ._SENT For_IN each_DT decision_NN point_NN we_PP recorded_VBD the_DT level_NN of_IN the_DT quality_NN of_IN the_DT information_NN used_VBN to_TO support_VB it_PP ._SENT A_DT regression_NN analysis_NN was_VBD performed_VBN to_TO assess_VB if_IN the_DT percentage_NN of_IN high_JJ quality_NN evidence_NN used_VBN in_IN the_DT guidelines_NNS development_NN was_VBD related_VBN to_TO the_DT overall_JJ quality_NN of_IN the_DT guidelines_NNS ._SENT Results_NNS |_SYM Three_CD guidelines_NNS were_VBD classified_VBN as_IN EB_NP ,_, three_CD as_IN CB-EB_NP and_CC two_CD as_IN CB_NP ._SENT The_DT EB_NP guidelines_NNS scored_VBD better_JJR than_IN CB_NP ,_, with_IN the_DT CB-EB_NP scoring_VBG in_IN the_DT middle_NN among_IN all_DT instruments_NNS for_IN guidelines_NNS quality_NN assessment_NN ._SENT No_DT major_JJ disagreement_NN in_IN recommendations_NNS was_VBD detected_VBN among_IN the_DT guidelines_NNS regardless_RB of_IN the_DT method_NN used_VBN for_IN development_NN ,_, but_CC the_DT EB_NP guidelines_NNS had_VBD a_DT better_JJR agreement_NN with_IN the_DT benchmark_JJ guideline_NN for_IN any_DT decision_NN point_NN ._SENT When_WRB the_DT source_NN of_IN evidence_NN used_VBN to_TO support_VB decision_NN were_VBD of_IN high_JJ quality_NN ,_, we_PP found_VBD a_DT higher_JJR level_NN of_IN full_JJ agreement_NN among_IN the_DT guidelines_NNS '_POS recommendations_NNS ._SENT Up_RB to_TO 94_CD %_NN of_IN variation_NN in_IN the_DT quality_NN score_NN among_IN guidelines_NNS could_MD be_VB explained_VBN by_IN the_DT quality_NN of_IN evidence_NN used_VBN for_IN guidelines_NNS development_NN ._SENT Conclusion_NN |_SYM EB_NP guidelines_NNS have_VBP a_DT better_JJR quality_NN than_IN CB_NP guidelines_NNS and_CC CB-EB_NP guidelines_NNS ._SENT Explicit_JJ use_NN of_IN high_JJ quality_NN evidence_NN can_MD lead_VB to_TO a_DT better_JJR agreement_NN among_IN recommendations_NNS ._SENT However_RB ,_, no_DT major_JJ disagreement_NN among_IN guidelines_NNS was_VBD noted_VBN regardless_RB of_IN the_DT method_NN for_IN their_PP$ development_NN ._SENT The_DT objective_NN of_IN guidelines_NNS development_NN is_VBZ to_TO assist_VB physicians_NNS and_CC patients_NNS in_IN making_VBG optimal_JJ health_NN care_NN decisions_NNS ,_, which_WDT in_IN turn_NN should_MD improve_VB the_DT quality_NN of_IN clinical_JJ practice_NN ._SENT Different_JJ methods_NNS are_VBP used_VBN to_TO develop_VB guidelines_NNS ._SENT Some_DT are_VBP developed_VBN by_IN a_DT consensus_NN of_IN experts_NNS while_IN others_NNS also_RB use_VBP a_DT formal_JJ way_NN to_TO appraise_VB the_DT literature_NN and_CC create_VB evidence-based_JJ (_( EB_NP )_) guidelines_NNS ._SENT In_IN general_JJ ,_, evidence-based_JJ guidelines_NNS are_VBP considered_VBN to_TO provide_VB better_JJR recommendations_NNS for_IN practice_NN than_IN consensus-based_JJ guidelines_NNS but_RB are_VBP time_NN consuming_NN and_CC expensive_JJ to_TO create_VB ._SENT This_DT belief_NN that_IN EB_NP guidelines_NNS are_VBP superior_JJ to_TO other_JJ types_NNS of_IN guideline_NN is_VBZ based_VBN on_IN our_PP$ normative_JJ views_NNS of_IN methods_NNS for_IN guidelines_NNS development_NN and_CC not_RB on_IN empirical_JJ comparison_NN of_IN practice_NN recommendations_NNS using_VBG different_JJ methods_NNS for_IN development_NN of_IN guidelines_NNS ._SENT To_TO date_VB no_DT formal_JJ evaluation_NN has_VBZ been_VBN performed_VBN to_TO detect_VB if_IN there_EX are_VBP differences_NNS in_IN the_DT quality_NN and_CC recommendations_NNS between_IN evidence-based_JJ and_CC consensus-based_JJ (_( CB_NP )_) guidelines_NNS ._SENT If_IN guidelines_NNS developed_VBN by_IN using_VBG consensus_NN or_CC evidence-based_JJ methods_NNS have_VBP the_DT same_JJ quality_NN and_CC agree_VB in_IN the_DT recommendations_NNS ,_, then_RB obviously_RB resources_NNS spent_VBN on_IN the_DT laborious_JJ and_CC time-consuming_JJ process_NN of_IN locating_VBG and_CC appraising_VBG evidence_NN can_MD be_VB used_VBN elsewhere_RB ._SENT Otherwise_RB ,_, if_IN evidence_NN based_VBN guidelines_NNS have_VBP a_DT better_JJR quality_NN and_CC their_PP$ recommendations_NNS differ_VBP from_IN those_DT guidelines_NNS produced_VBN by_IN consensus_NN ,_, then_RB creation_NN of_IN evidence_NN based_VBN guidelines_NNS may_MD become_VB the_DT only_JJ acceptable_JJ method_NN of_IN guideline_NN development_NN ._SENT In_IN this_DT paper_NN ,_, we_PP explore_VBP if_IN there_EX are_VBP differences_NNS in_IN the_DT quality_NN and_CC recommendations_NNS between_IN EB_NP and_CC CB_NP guidelines_NNS ._SENT To_TO enable_VB meaningful_JJ comparison_NN ,_, multiple_JJ recommendations_NNS produced_VBN by_IN a_DT given_VBN guideline_NN method_NN should_MD be_VB available_JJ ._SENT This_DT objective_NN is_VBZ best_RBS met_VBN by_IN focusing_VBG on_IN the_DT guidelines_NNS that_WDT comprehensively_RB attempt_VBP to_TO guide_VB clinicians_NNS in_IN the_DT management_NN of_IN one_CD disorder_NN ._SENT Since_IN breast_NN cancer_NN is_VBZ an_DT important_JJ disease_NN and_CC various_JJ organizations_NNS have_VBP produced_VBN guidelines_NNS using_VBG different_JJ methods_NNS ,_, we_PP conducted_VBD a_DT comparison_NN study_NN of_IN comprehensive_JJ breast_NN cancer_NN guidelines_NNS ._SENT We_PP assessed_VBD both_CC the_DT differences_NNS in_IN the_DT quality_NN as_IN measured_VBN by_IN using_VBG different_JJ quality_NN instruments_NNS assessment_NN and_CC the_DT level_NN of_IN agreement_NN among_IN guidelines_NNS according_VBG to_TO the_DT method_NN of_IN development_NN ._SENT 1_LS ._SENT Identification_NN and_CC assessment_NN of_IN instruments_NNS for_IN measurement_NN of_IN the_DT quality_NN of_IN guidelines_NNS Since_IN there_EX is_VBZ no_DT uniformly_RB accepted_VBN instrument_NN for_IN evaluation_NN of_IN the_DT quality_NN of_IN guidelines_NNS ,_, we_PP first_RB performed_VBD a_DT comprehensive_JJ literature_NN search_NN to_TO identify_VB published_VBN tools_NNS for_IN assessment_NN of_IN clinical_JJ practice_NN guideline_NN quality_NN ._SENT We_PP searched_VBD MEDLINE_NP (_( 1996_NP --_: 2000_LS )_) using_VBG the_DT keywords_NNS :_: guidelines_NNS ,_, practice_NN guidelines_NNS ,_, quality_NN ,_, "_'' weights_NNS and_CC measures_NNS "_'' ,_, "_`` scale_NN "_'' ,_, psychometrics_NNS ,_, reproducibility_NN ._SENT Any_DT article_NN considered_VBD relevant_JJ to_TO evaluate_VB quality_NN of_IN guidelines_NNS was_VBD retrieved_VBN ._SENT The_DT list_NN of_IN references_NNS of_IN each_DT article_NN was_VBD also_RB scanned_VBN ._SENT After_IN an_DT assessment_NN of_IN 14_CD papers_NNS by_IN four_CD of_IN us_PP ,_, four_CD instruments_NNS to_TO assess_VB the_DT quality_NN of_IN guidelines_NNS were_VBD identified_VBN ._SENT An_DT additional_JJ instrument_NN (_( SIGN_NP )_) was_VBD identified_VBN through_IN Evidence-based_JJ Health_NP Discussion_NP Group_NP ._SENT For_IN additional_JJ details_NNS on_IN the_DT instruments_NNS for_IN evaluation_NN of_IN guidelines_NNS readers_NNS are_VBP referred_VBN to_TO the_DT Appendix_NN (_( see_VB )_) ._SENT To_TO assess_VB their_PP$ reliability_NN and_CC reproducibility_NN ,_, we_PP applied_VBD all_DT identified_VBN instruments_NNS to_TO each_DT guideline_NN (_( see_VB below_IN )_) ._SENT We_PP calculated_VBD the_DT coefficient_NN of_IN agreement_NN (_( kappa_NN )_) among_IN evaluators_NNS for_IN each_DT guideline_NN ._SENT A_DT good_JJ interobserver_NN agreement_NN was_VBD considered_VBN if_IN kappa_NN value_NN exceeded_VBD 0.4_CD ._SENT In_IN our_PP$ evaluation_NN ,_, two_CD instruments_NNS had_VBD a_DT kappa_NN interobserver_NN agreement_NN K_NP >_SYM 0.4_CD among_IN all_DT investigators_NNS in_IN 6_CD of_IN 8_CD guidelines_NNS ._SENT When_WRB it_PP comes_VBZ to_TO evaluation_NN of_IN the_DT quality_NN of_IN breast_NN cancer_NN guidelines_NNS these_DT instruments_NNS performed_VBD better_JJR than_IN others_NNS and_CC probably_RB can_MD be_VB recommended_VBN for_IN future_JJ use_NN ._SENT Table_NP 1_CD |_SYM Interobserver_NN agreement_NN of_IN instruments_NNS for_IN assessment_NN of_IN the_DT guidelines_NNS quality_NN 2_CD ._SENT Identification_NN and_CC classification_NN of_IN breast_NN cancer_NN guidelines_NNS A_DT literature_NN search_NN was_VBD conducted_VBN for_IN published_VBN breast_NN cancer_NN guidelines_NNS using_VBG MEDLINE_NP for_IN the_DT years_NNS 1996_CD --_: April_NP 2000_CD ._SENT The_DT following_VBG keywords_NNS were_VBD used_VBN in_IN combination_NN :_: Guidelines_NNS ,_, Practice_NP Guidelines_NPS ,_, recommendations_NNS ,_, breast_NN neoplasms_NNS ._SENT An_DT Internet_NP search_NN was_VBD also_RB performed_VBN ,_, using_VBG the_DT method_NN described_VBN by_IN Sanders_NP et_CC al_NP ._SENT 131_CD articles_NNS were_VBD retrieved_VBN ,_, and_CC reviewed_VBN for_IN their_PP$ content_NN ._SENT We_PP considered_VBD any_DT article_NN that_WDT fit_VBP the_DT definition_NN of_IN the_DT National_NP Library_NP of_IN Medicine_NP for_IN practice_NN guidelines_NNS :_: directions_NNS or_CC principles_NNS presenting_VBG current_JJ or_CC future_JJ rules_NNS of_IN policy_NN for_IN the_DT health_NN care_NN practitioner_NN to_TO assist_VB him_PP in_IN patient_JJ care_NN decisions_NNS regarding_VBG diagnosis_NN ,_, therapy_NN ,_, or_CC related_JJ clinical_JJ circumstances_NNS ._SENT Eight_CD papers_NNS referred_VBD to_TO breast_VB cancer_NN guidelines_NNS ,_, and_CC were_VBD selected_VBN for_IN the_DT analysis_NN ._SENT Each_DT guideline_NN was_VBD classified_VBN as_IN CB_NP ,_, when_WRB there_EX was_VBD no_DT consideration_NN about_IN the_DT quality_NN of_IN evidence_NN used_VBN to_TO make_VB practice_NN recommendations_NNS ;_: as_IN EB_NP ,_, when_WRB there_EX was_VBD an_DT explicit_JJ consideration_NN of_IN the_DT quality_NN of_IN evidence_NN in_IN the_DT development_NN of_IN guidelines_NNS ;_: or_CC as_IN consensus_NN based_VBN with_IN no_DT explicit_JJ consideration_NN of_IN evidence_NN (_( CB-EB_NP )_) when_WRB there_EX were_VBD considerations_NNS about_IN the_DT evidence_NN ,_, but_CC not_RB in_IN explicit_JJ manner_NN ._SENT From_IN these_DT eight_CD guidelines_NNS ,_, three_CD were_VBD classified_VBN as_IN EB_NP three_CD as_IN CB-EB_NP and_CC two_CD as_IN CB_NP ._SENT Table_NP 2_CD |_SYM Classification_NN of_IN Breast_NP Cancer_NP Guidelines_NNS according_VBG to_TO the_DT method_NN of_IN development_NN ._SENT 3_LS ._SENT Evaluation_NN of_IN guidelines_NNS Each_DT guideline_NN was_VBD evaluated_VBN independently_RB by_IN three_CD of_IN us_PP using_VBG each_DT of_IN the_DT instruments_NNS ._SENT All_DT discordances_NNS were_VBD resolved_VBN by_IN a_DT consensus_NN meeting_NN ._SENT Each_DT guideline_NN was_VBD scored_VBN according_VBG to_TO the_DT instructions_NNS of_IN each_DT instrument_NN ._SENT The_DT quality_NN and_CC rank_NN was_VBD determined_VBN by_IN the_DT quotient_NN of_IN items_NNS scored_VBN positively_RB by_IN the_DT total_JJ items_NNS scored_VBN for_IN each_DT instrument_NN ._SENT 4_LS ._SENT Evaluation_NN of_IN agreement_NN among_IN guidelines_NNS Using_VBG instruments_NNS to_TO evaluate_VB practice_NN guidelines_NNS yields_NNS conclusions_NNS regarding_VBG normative_JJ aspects_NNS of_IN the_DT guidelines_NNS development_NN ,_, but_CC does_VBZ not_RB necessarily_RB mean_VB that_IN recommendations_NNS provided_VBN by_IN guidelines_NNS using_VBG different_JJ methods_NNS will_MD produce_VB different_JJ management_NN advice_NN to_TO our_PP$ patients_NNS ._SENT To_TO assess_VB if_IN recommendations_NNS among_IN various_JJ guidelines_NNS differ_VBP ,_, we_PP need_VBP to_TO determine_VB the_DT level_NN of_IN agreement_NN among_IN guidelines_NNS for_IN each_DT specific_JJ decision_NN point_NN ._SENT Since_IN NCCN_NP (_( National_NP Comprehensive_NP Cancer_NP Network_NP )_) guidelines_NNS were_VBD presented_VBN in_IN explicit_JJ ,_, algorithmic_JJ format_NN ,_, we_PP used_VBD this_DT one_CD to_TO identify_VB the_DT decision_NN points_NNS for_IN matched_VBN comparison_NN with_IN other_JJ guidelines_NNS ._SENT These_DT guidelines_NNS have_VBP been_VBN developed_VBN by_IN the_DT leading_VBG 18_CD cancer_NN institutions_NNS in_IN the_DT US_NP and_CC have_VBP been_VBN constantly_RB updated_VBN and_CC re-evaluated_NN ._SENT They_PP have_VBP also_RB been_VBN developed_VBN to_TO closely_RB mimic_VB clinical_JJ practice_NN ._SENT Therefore_RB ,_, we_PP feel_VBP that_DT selection_NN of_IN decision_NN points_NNS based_VBN on_IN the_DT NCCN_NP guidelines_NNS were_VBD appropriate_JJ ._SENT We_PP identified_VBD fourteen_NN decision_NN points_NNS in_IN the_DT management_NN of_IN stage_NN I_PP and_CC II_NP breast_NN cancer_NN that_WDT were_VBD linked_VBN to_TO specific_JJ recommendations_NNS in_IN the_DT other_JJ guidelines_NNS for_IN our_PP$ comparison_NN ._SENT Comparison_NN of_IN recommendations_NNS for_IN advanced_JJ stages_NNS of_IN breast_NN cancer_NN has_VBZ not_RB been_VBN performed_VBN since_IN there_EX was_VBD only_RB one_CD guideline_NN that_WDT included_VBD it_PP ._SENT Subsequently_RB ,_, four_CD of_IN us_PP evaluated_VBD each_DT of_IN these_DT decision_NN points_NNS in_IN each_DT guideline_NN examining_VBG level_NN of_IN agreement_NN among_IN various_JJ guidelines_NNS ._SENT Since_IN matching_VBG between_IN recommendations_NNS in_IN the_DT guidelines_NNS that_WDT were_VBD presented_VBN in_IN non-algorithmic_JJ format_NN was_VBD poor_JJ ,_, we_PP decided_VBD to_TO use_VB NCCN_NP guidelines_NNS as_IN a_DT benchmark_NN ._SENT We_PP classified_VBD agreement_NN of_IN each_DT guideline_NN with_IN the_DT NCCN_NP guidelines_NNS as_IN having_VBG full_JJ agreement_NN ,_, partial_JJ agreement_NN and_CC disagreement_NN ._SENT It_PP was_VBD considered_VBN that_IN guidelines_NNS agree_VBP with_IN the_DT NCCN_NP if_IN the_DT management_NN recommendation_NN was_VBD the_DT same_JJ ;_: the_DT guidelines_NNS were_VBD considered_VBN to_TO disagree_VB if_IN they_PP provided_VBD different_JJ recommendations_NNS ._SENT A_DT partial_JJ agreement_NN was_VBD judged_VBN to_TO exist_VB if_IN the_DT guideline_NN recommended_VBD the_DT same_JJ management_NN but_CC in_IN a_DT broadly_RB defined_VBN sense_NN and_CC not_RB in_IN explicit_JJ ,_, clear_JJ manner_NN ._SENT Each_DT of_IN these_DT decision_NN points_NNS was_VBD also_RB classified_VBN as_IN supported_VBN by_IN high_JJ quality_NN evidence_NN or_CC not_RB ._SENT High_JJ quality_NN evidence_NN was_VBD considered_VBN to_TO be_VB based_VBN on_IN randomized_VBN trials_NNS (_( RCT_NP )_) or_CC systematic_JJ reviews_NNS (SR)/meta-analysis_NN (_( MA_NN )_) ._SENT If_IN the_DT quality_NN evidence_NN was_VBD not_RB based_VBN on_IN RCT_NP or_CC SR/MA_NP or_CC was_VBD not_RB stated_VBN ,_, it_PP was_VBD classified_VBN as_IN low_JJ quality_NN evidence_NN ._SENT Subsequently_RB ,_, we_PP performed_VBD a_DT regression_NN analysis_NN to_TO assess_VB the_DT contribution_NN of_IN the_DT quality_NN of_IN evidence_NN to_TO the_DT total_JJ score_NN obtained_VBN by_IN each_DT instrument_NN for_IN the_DT evaluation_NN of_IN the_DT guidelines_NNS quality_NN ._SENT Independent_JJ variable_NN was_VBD the_DT proportion_NN of_IN decisions_NNS supported_VBN by_IN high_JJ quality_NN evidence_NN while_IN dependent_JJ variable_NN was_VBD score_NN obtained_VBN by_IN each_DT instrument_NN ._SENT A_DT regression_NN analysis_NN was_VBD performed_VBN after_IN it_PP has_VBZ assessed_VBN that_IN the_DT distribution_NN of_IN the_DT variables_NNS was_VBD normal_JJ by_IN Wilks-Shapiro_NP test_NN ._SENT Evaluation_NN of_IN the_DT quality_NN of_IN guidelines_NNS |_SYM The_DT results_NNS of_IN the_DT quality_NN of_IN each_DT guideline_NN according_VBG to_TO each_DT instrument_NN are_VBP shown_VBN in_IN Table_NP ._SENT Overall_RB ,_, EB_NP guidelines_NNS had_VBD higher_JJR scores_NNS than_IN CB_NP ,_, and_CC the_DT CB-EB_NP category_NN ranked_VBD in_IN the_DT middle_NN ._SENT As_IN expected_VBN ,_, the_DT instruments_NNS for_IN the_DT evaluation_NN of_IN quality_NN are_VBP based_VBN on_IN the_DT number_NN of_IN desired_VBN built-in_JJ normative_JJ features_NNS of_IN good_JJ guidelines_NNS development_NN ,_, as_RB initially_RB recommended_VBN by_IN Institute_NP of_IN Medicine_NP ._SENT This_DT is_VBZ further_RBR confirmed_VBN by_IN the_DT evaluation_NN of_IN the_DT contribution_NN of_IN the_DT quality_NN of_IN evidence_NN to_TO the_DT final_JJ quality_NN score_NN :_: the_DT regression_NN analysis_NN performed_VBN showed_VBD that_IN the_DT quality_NN of_IN guidelines_NNS ,_, as_RB measured_VBN by_IN these_DT instruments_NNS ,_, is_VBZ a_DT function_NN of_IN the_DT percentage_NN of_IN high_JJ quality_NN evidence_NN that_IN each_DT guideline_NN contains_VBZ ._SENT This_DT suggests_VBZ that_IN evidence_NN plays_VBZ a_DT major_JJ role_NN in_IN the_DT composition_NN of_IN the_DT quality_NN scales_NNS ._SENT If_IN the_DT quality_NN of_IN evidence_NN is_VBZ poor_JJ ,_, paying_VBG attention_NN to_TO other_JJ quality_NN domains_NNS in_IN the_DT development_NN of_IN guidelines_NNS will_MD not_RB result_VB in_IN higher_JJR quality_NN scores_NNS ._SENT Fig_NP illustrates_VBZ a_DT relationship_NN between_IN the_DT quality_NN of_IN evidence_NN and_CC the_DT total_JJ quality_NN score_NN using_VBG the_DT two_CD instruments_NNS that_WDT achieved_VBD best_JJS agreement_NN among_IN evaluators_NNS ._SENT It_PP is_VBZ quite_RB remarkable_JJ to_TO note_VB that_IN up_RB to_TO >94_JJ %_NN variation_NN in_IN the_DT score_NN could_MD be_VB explained_VBN by_IN the_DT quality_NN of_IN evidence_NN alone_RB ._SENT Figure_NP 1_CD |_SYM Average_JJ score_NN of_IN each_DT guideline_NN according_VBG to_TO the_DT method_NN of_IN development_NN Average_JJ score_NN of_IN each_DT guideline_NN according_VBG to_TO the_DT method_NN of_IN development_NN Acronyms_NNS and_CC abbreviations_NNS :_: ACCC_NP --_: Association_NP of_IN Community_NP Cancer_NP Centers_NPS ;_: CMA-Canadian_NP Medical_NP Association_NP ;_: ICSI_NP --_: Institute_NP for_IN Clinical_NP Systems_NPS Improvement_NP ;_: MPS_NP --_: Multi_NNS Professional_NP Societies_NP ;_: NCCN_NP --_: National_NP Comprehensive_NP Cancer_NP Network_NP ;_: NHMRC_NP --_: The_DT National_NP Health_NP and_CC Medical_NP Research_NP Council_NP ;_: SIGN_NP --_: Scottish_NP Intercollegiate_NP Guidelines_NPS Network_NP ;_: SSO_NP --_: Society_NP of_IN Surgical_NP Oncology_NP ._SENT EB_NP :_: evidence-based_JJ guidelines_NNS ;_: CB_NP :_: consensus-based_JJ guidelines_NNS EB-CB_NN :_: consensus-based_JJ guidelines_NNS with_IN no_DT explicit_JJ considerations_NNS of_IN evidence_NN Figure_NP 2_CD |_SYM A_DT relationship_NN between_IN quality_NN of_IN evidence_NN and_CC total_JJ guideline_NN quality_NN score_NN ._SENT A_DT relationship_NN between_IN quality_NN of_IN evidence_NN and_CC total_JJ guideline_NN quality_NN score_NN ._SENT Note_NN that_IN up_RB to_TO 94_CD %_NN of_IN variation_NN in_IN the_DT quality_NN score_NN can_MD be_VB explained_VBN by_IN the_DT quality_NN of_IN evidence_NN ._SENT Table_NP 3_CD |_SYM Quality_JJ of_IN breast_NN cancer_NN guidelines_NNS Evaluation_NN of_IN agreement_NN among_IN guidelines_NNS |_SYM The_DT agreement_NN among_IN each_DT guideline_NN for_IN the_DT 14_CD decision_NN points_NNS is_VBZ shown_VBN in_IN Table_NP ._SENT We_PP obtained_VBD no_DT major_JJ disagreements_NNS among_IN guidelines_NNS ,_, but_CC the_DT EB_NP guidelines_NNS had_VBD a_DT better_JJR agreement_NN with_IN the_DT decision_NN points_NNS in_IN any_DT situation_NN than_IN CB-guidelines_NP and_CC CB-EB_NP guidelines_NNS ._SENT The_DT fact_NN that_IN no_DT major_JJ disagreements_NNS were_VBD seen_VBN regardless_RB the_DT method_NN of_IN development_NN can_MD probably_RB be_VB explained_VBN by_IN the_DT vagueness_NN of_IN recommendations_NNS by_IN CB_NP guidelines_NNS ._SENT As_IN shown_VBN in_IN Table_NP ,_, the_DT number_NN of_IN decision_NN points_NNS supported_VBN by_IN high_JJ quality_NN evidence_NN is_VBZ highest_JJS in_IN the_DT EB_NP guidelines_NNS and_CC zero_NN in_IN CB_NP guidelines_NNS ._SENT The_DT use_NN of_IN high_JJ quality_NN evidence_NN was_VBD significantly_RB associated_VBN with_IN a_DT higher_JJR level_NN of_IN concordance_NN among_IN the_DT decision_NN points_NNS ._SENT When_WRB the_DT source_NN of_IN evidence_NN was_VBD of_IN good_JJ quality_NN (_( RCT_NP or_CC SR_NN )_) ,_, we_PP had_VBD 18_CD full_JJ agreements_NNS and_CC 23_CD partial_JJ agreements_NNS (_( Chi_NP square_RB =_SYM 0.610_CD ,_, degrees_NNS of_IN freedom_NN =_SYM 1_CD ,_, p_NN =_SYM 0.435_CD )_) ._SENT When_WRB the_DT source_NN of_IN evidence_NN was_VBD not_RB stated_VBN or_CC was_VBD of_IN lower_JJR quality_NN ,_, we_PP had_VBD 17_CD full_JJ agreements_NNS and_CC 40_CD partial_JJ agreements_NNS (_( Chi-Square_NP 9.281_CD ,_, Degrees_NP of_IN freedom_NN 2_CD ,_, p=_NP 0.002_CD )_) ._SENT This_DT means_VBZ that_IN recommendations_NNS based_VBN on_IN high_JJ quality_NN evidence_NN may_MD lead_VB to_TO less_JJR disagreement_NN and_CC potentially_RB less_JJR practice_NN variation_NN ._SENT Table_NP 4_CD |_SYM Level_NP of_IN agreement_NN between_IN NCCN_NP guideline_NN and_CC other_JJ breast_NN cancer_NN guidelines_NNS ._SENT Guidelines_NNS have_VBP been_VBN increasingly_RB used_VBN in_IN medical_JJ decision-making_NN ._SENT Different_JJ methods_NNS have_VBP been_VBN used_VBN in_IN guideline_NN development_NN ._SENT Does_VBZ it_PP matter_VB how_WRB guidelines_NNS were_VBD produced_VBN ?_SENT Most_JJS authors_NNS believe_VBP that_IN it_PP matters_VBZ very_RB much_JJ and_CC that_IN guidelines_NNS produced_VBD using_VBG evidence-based_JJ methods_NNS are_VBP superior_JJ to_TO other_JJ methodologies_NNS of_IN development_NN ._SENT However_RB ,_, empirical_JJ investigations_NNS to_TO assess_VB if_IN guidelines_NNS produced_VBN by_IN different_JJ methods_NNS have_VBP different_JJ quality_NN and_CC result_NN in_IN different_JJ recommendations_NNS have_VBP not_RB been_VBN performed_VBN ._SENT Here_RB ,_, we_PP report_VBP such_PDT a_DT study_NN ._SENT Using_VBG formal_JJ instruments_NNS for_IN evaluation_NN of_IN the_DT quality_NN of_IN guidelines_NNS we_PP found_VBD that_IN EB-guidelines_NP had_VBD substantially_RB higher_JJR score_NN than_IN CB-guidelines_NNS or_CC guideline_NN that_WDT considered_VBD evidence_NN in_IN a_DT less_RBR formal_JJ way_NN (_( CB-EB_NP )_) ._SENT As_IN discussed_VBN above_IN (_( see_VB Results_NNS )_) ,_, this_DT is_VBZ not_RB a_DT surprising_JJ result_NN ,_, since_IN the_DT instruments_NNS for_IN the_DT guidelines_NNS evaluation_NN measure_NN the_DT quality_NN based_VBN on_IN the_DT number_NN of_IN desired_VBN normative_JJ characteristics_NNS in_IN a_DT particular_JJ guideline_NN ._SENT Since_IN appraisal_NN of_IN evidence_NN is_VBZ considered_VBN inherently_RB important_JJ for_IN the_DT development_NN of_IN a_DT good_JJ guideline_NN ,_, one_PP would_MD then_RB expect_VB that_IN the_DT guidelines_NNS that_WDT pay_VBP more_JJR attention_NN to_TO its_PP$ evidence_NN basis_NN (_( i.e._FW ,_, those_DT that_WDT are_VBP evidence-based_JJ )_) would_MD receive_VB higher_JJR quality_NN score_NN than_IN other_JJ types_NNS of_IN the_DT guidelines_NNS (_( i.e._FW guidelines_NNS developed_VBN solely_RB by_IN a_DT consensus_NN process_NN )_) (_( see_VB Fig_NP )_) ._SENT This_DT is_VBZ also_RB evident_JJ in_IN our_PP$ finding_VBG that_DT variation_NN in_IN the_DT total_JJ quality_NN score_NN can_MD be_VB up_RB to_TO 94_CD %_NN explained_VBN by_IN the_DT quality_NN of_IN evidence_NN (_( see_VB Fig_NP )_) ._SENT Not_RB all_DT instruments_NNS for_IN evaluation_NN of_IN guidelines_NNS performed_VBN equally_RB well_RB ._SENT Only_RB two_CD of_IN the_DT instruments_NNS available_JJ to_TO address_VB the_DT quality_NN of_IN guidelines_NNS had_VBD a_DT good_JJ level_NN of_IN agreement_NN among_IN evaluators_NNS (_( k_NN >_SYM 0.4_CD )_) in_IN most_JJS of_IN guidelines_NNS ._SENT This_DT result_NN raises_VBZ concern_NN about_IN the_DT reproducibility_NN of_IN results_NNS using_VBG the_DT other_JJ instruments_NNS reported_VBN in_IN the_DT literature_NN ._SENT In_IN general_NN ,_, a_DT few_JJ studies_NNS have_VBP been_VBN done_VBN to_TO evaluate_VB reproducibility_NN of_IN the_DT instruments_NNS for_IN assessment_NN of_IN the_DT guidelines_NNS quality_NN ._SENT Any_DT future_JJ study_NN attempting_VBG to_TO address_VB the_DT quality_NN of_IN guidelines_NNS should_MD take_VB this_DT finding_NN into_IN account_NN ._SENT A_DT more_RBR interesting_JJ question_NN is_VBZ to_TO assess_VB if_IN the_DT recommendations_NNS among_IN guidelines_NNS produced_VBN by_IN different_JJ methods_NNS actually_RB differ_VBP ._SENT We_PP found_VBD no_DT instance_NN of_IN total_JJ disagreement_NN among_IN guidelines_NNS regardless_RB of_IN the_DT method_NN of_IN development_NN ._SENT We_PP also_RB found_VBD that_IN EB_NP and_CC CB-EB_NP guidelines_NNS had_VBD more_JJR points_NNS of_IN agreement_NN with_IN our_PP$ benchmark_JJ guidelines_NNS (_( NCCN_NP )_) than_IN guidelines_NNS developed_VBD using_VBG exclusively_RB consensus_NN method_NN ._SENT We_PP also_RB found_VBD that_IN when_WRB high-quality_JJ evidence_NN existed_VBN in_IN the_DT literature_NN (_( see_VB Results_NNS )_) less_CC disagreement_NN was_VBD found_VBN among_IN various_JJ guidelines_NNS ._SENT This_DT is_VBZ not_RB completely_RB surprising_JJ because_IN formulation_NN of_IN guidelines_NNS does_VBZ not_RB happen_VB in_IN a_DT vacuum_NN ._SENT Most_JJS guideline_NN developers_NNS are_VBP experts_NNS in_IN the_DT field_NN who_WP have_VBP knowledge_NN of_IN the_DT literature_NN ._SENT When_WRB evidence_NN is_VBZ unequivocal_JJ ,_, less_JJR disagreement_NN may_MD be_VB expected_VBN ._SENT Consequently_RB ,_, less_JJR practice_NN variation_NN may_MD be_VB found_VBN when_WRB high-quality_JJ evidence_NN exists_VBZ ._SENT In_IN conclusion_NN ,_, EB_NP guidelines_NNS have_VBP a_DT better_JJR quality_NN than_IN CB_NP guidelines_NNS as_RB measured_VBN by_IN the_DT quality_NN assessment_NN instruments_NNS used_VBN in_IN this_DT study_NN ._SENT The_DT explicit_JJ use_NN of_IN high_JJ quality_NN evidence_NN is_VBZ desirable_JJ and_CC can_MD lead_VB to_TO a_DT better_JJR agreement_NN among_IN recommendations_NNS ._SENT However_RB ,_, no_DT major_JJ disagreement_NN among_IN guidelines_NNS was_VBD noted_VBN regardless_RB of_IN the_DT method_NN for_IN their_PP$ development_NN ._SENT none_NN declared_VBD We_PP thank_VBP Dr.Stephen_NP Edge_NP for_IN reviewing_VBG our_PP$ paper_NN and_CC his_PP$ helpful_JJ comments_NNS and_CC constructive_JJ critique_NN ._SENT 